Results

CBOE Holdings Inc.

06/06/2019 | Press release | Distributed by Public on 06/06/2019 06:37

vTv Therapeutics Reports Topline Results From Part 1 Of Phase 2 Simplici-T1 Trial In Patients With Type 1 Diabetes: 'shows statistically significant reduction in HbA1c without[...]

Cboe - Market News Story

vTv Therapeutics Reports Topline Results From Part 1 Of Phase 2 Simplici-T1 Trial In Patients With Type 1 Diabetes: 'shows statistically significant reduction in HbA1c without increases in ketones or hypoglycemia'

Benzinga Newsdesk 6/6/2019 7:02:08 AM

vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from the primary analysis of Part 1 of the Phase 2 Simplici-T1 trial assessing the liver-selective glucokinase activator TTP399 in adult patients with type 1 diabetes (T1D).

In this double-blind, placebo-controlled 12-week trial, the baseline mean HbA1c for the groups treated with TTP399 and placebo was 7.3% and 7.4%, respectively. Patients treated with TTP399 (n=8) showed a statistically significant mean reduction in HbA1c of 0.6% at 12 weeks, while the group treated with placebo (n=11) showed a mean increase in HbA1c of 0.1%, resulting in a mean difference of 0.7% in the TTP399 group relative to the placebo group (p=0.03). At the same time, trends toward decreased insulin usage were observed in the group treated with TTP399.

Patients in this study received insulin adjustments to optimize glucose levels. As a result, the primary analysis included a responder analysis in which a 'treatment responder' was defined as a patient who had a decrease in HbA1c at Week 12, no abnormal lactate or ketones detected in blood or urine during the study, and no increased time in Level 2 hypoglycemia (blood glucose <54 mg/dl). Of all study patients, there was a greater proportion of responders in the group treated with TTP399 (75%) than in the placebo group (9%) (p=0.006). Consistent with the treatment responder results, abnormal ketones were observed in plasma or urine in 63% of patients on placebo vs. 13% of patients treated with TTP399.

TTP399 was well tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class. The study had no serious adverse event reported. The study also had no report of diabetic ketoacidosis or severe hypoglycemia.

'These results from a small group of patients with type 1 diabetes are very exciting. If they hold up in part 2 of the trial, TTP399 will be the most impressive adjunctive therapy to insulin in type 1 diabetes care,' said Dr. John Buse, director of the North Carolina Translational and Clinical Sciences Institute and of the Diabetes Center at the University of North Carolina School of Medicine and principal investigator for this study.

More detailed study results will be presented at the 55th Annual Meeting of the European Association for the Study of Diabetes held in Barcelona in September.

'While insulin remains the main line of treatment for T1D, we believe that adjunctive treatments such as TTP399 can lead to improvements in metabolic balance and favorable treatment outcomes for people living with T1D,' said Esther Latres, Ph.D., JDRF Director Research. 'We are encouraged by the initial results and look forward to critical additional evidence to ascertain the benefits of this therapy and laud the efforts of vTv Therapeutics for their innovative approach to address unmet clinical needs.'

'We are excited that TTP399 has demonstrated clinically meaningful efficacy as an adjunct therapy for T1D in this group of patients, and are pleased to have seen a favorable safety profile consistent with what we have seen in our previous trials in patients with type 2 diabetes,' said Steve Holcombe, President and CEO of vTv Therapeutics. 'Given the well-controlled patient population in this part of the trial, we look forward to the results from part 2 in a broader patient population expected in Q1 2020.'